Pharmacotherapy of type 2 diabetes: An update

被引：153

作者：

Upadhyay, Jagriti ^{[1
,2
]}

Polyzos, Stergios A. ^{[3
]}

Perakakis, Nikolaos ^{[2
,4
,5
]}

Thakkar, Bindiya ^{[1
]}

Paschou, Stavroula A. ^{[2
]}

Katsiki, Niki ^{[6
]}

Underwood, Patricia ^{[1
]}

Park, Kyung-Hee ^{[7
]}

Seufert, Jochen ^{[4
,5
]}

Kang, Eun Seok ^{[8
]}

Sternthal, Elliot ^{[1
]}

Karagiannis, Asterios ^{[3
]}

Mantzoros, Christos S. ^{[1
,2
]}

机构：

[1] Boston VA Healthcare Syst, Sect Endocrinol Diabet & Metab, Boston, MA 02130 USA

[2] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, Dept Internal Med, Boston, MA 02115 USA

[3] Aristotle Univ Thessaloniki, Med Sch, Dept Pharmacol 1, Thessaloniki, Greece

[4] Univ Hosp Freiburg, Div Endocrinol, Dept Internal Med 2, Freiburg, Germany

[5] Univ Hosp Freiburg, Div Diabetol, Dept Internal Med 2, Freiburg, Germany

[6] Aristotle Univ Thessaloniki, Med Sch, Hippocrat Hosp, Propedeut Dept Internal Med 2, Thessaloniki, Greece

[7] Hallym Univ Sacred Heart Hosp, Dept Family Med, Gyeonggi Do, South Korea

[8] Yonsei Univ, Coll Med, Div Endocrinol & Metab, Dept Internal Med, Seoul, South Korea

来源：

METABOLISM-CLINICAL AND EXPERIMENTAL | 2018年 / 78卷

关键词：

Algorithm; Goals pharmacotherapy; Personalized therapy; Type; 2; diabetes; GLUCAGON-LIKE PEPTIDE-1; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; IMPROVES GLYCEMIC CONTROL; CARDIOVASCULAR RISK-FACTORS; PLACEBO-CONTROLLED TRIAL; TWICE-DAILY EXENATIDE; HUMAN GLP-1 ANALOG; BETA-CELL FUNCTION; GLUCOSE COTRANSPORTER-2 INHIBITORS; PREVIOUS MYOCARDIAL-INFARCTION;

D O I：

10.1016/j.metabol.2017.08.010

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Type 2 diabetes (T2DM) is a leading cause of morbidity and mortality worldwide and a major economic burden. The prevalence of T2DM is rising, suggesting more effective prevention and treatment strategies are necessary. The aim of this narrative review is to summarize the pharmacologic treatment options available for patients with T2DM. Each therapeutic class is presented in detail, outlining medication effects, side effects, glycemic control, effect on weight, indications and contraindications, and use in selected populations (heart failure, renal insufficiency, obesity and the elderly). We also present representative cost for each antidiabetic category. Then, we provide an individualized guide for initiation and intensification of treatment and discuss the considerations and rationale for an individualized glycemic goal. (C) 2017 Elsevier Inc. All rights reserved.

引用

页码：13 / 42

页数：30

共 358 条

[1] Variations in tissue selectivity amongst insulin secretagogues: a systematic review [J].

Abdelmoneim, A. S. ;

Hasenbank, S. E. ;

Seubert, J. M. ;

Brocks, D. R. ;

Light, P. E. ;

Simpson, S. H. .

DIABETES OBESITY & METABOLISM, 2012, 14 (02) :130-138

[2] SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study [J].

Abdul-Ghani, Muhammad ;

Del Prato, Stefano ;

Chilton, Robert ;

DeFronzo, Ralph A. .

DIABETES CARE, 2016, 39 (05) :717-725

[3] The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men [J].

Agerso, H ;

Jensen, LB ;

Elbrond, B ;

Rolan, P ;

Zdravkovic, M .

DIABETOLOGIA, 2002, 45 (02) :195-202

[4] Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies [J].

Ahren, Bo ;

Mathieu, Chantal ;

Bader, Giovanni ;

Schweizer, Anja ;

Foley, James E. .

DIABETOLOGIA, 2014, 57 (07) :1304-1307

[5] The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus [J].

Alba, Maria ;

Xie, John ;

Fung, Albert ;

Desai, Mehul .

CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (08) :1375-1385

[6] The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem [J].

Alvarez, E ;

Martínez, MD ;

Roncero, I ;

Chowen, JA ;

García-Cuartero, B ;

Gispert, JD ;

Sanz, C ;

Vázquez, P ;

Maldonado, A ;

de Cáceres, J ;

Desco, M ;

Pozo, MA ;

Blázquez, E .

JOURNAL OF NEUROCHEMISTRY, 2005, 92 (04) :798-806

[7] Economic Costs of Diabetes in the U.S. in 2012 [J].

Yang W. ;

Dall T.M. ;

Halder P. ;

Gallo P. ;

Kowal S.L. ;

Hogan P.F. ;

Petersen M. .

DIABETES CARE, 2013, 36 (04) :1033-1046

[8]

Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS67, DOI [10.2337/dc13-S067, 10.2337/dc14-S081, 10.2337/dc11-S062, 10.2337/dc10-S011, 10.2337/dc13-S011, 10.2337/dc11-S011, 10.2337/dc10-S062, 10.2337/dc12-s011, 10.2337/dc12-s064]

[9] Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis [J].

Amori, Renee E. ;

Lau, Joseph ;

Pittas, Anastassios G. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (02) :194-206

[10]

Anderson JE, 2016, J FAM PRACTICE, V65, pS23

← 1 2 3 4 5 6 7 8 9 10 →